Stacking Amgen against its biggest biotech competitors on revenue growth, profitability, and valuation is one of the most practical ways to determine whether AMGN deserves a premium or a discount. An Amgen vs competitors analysis reveals where the company excels, where it falls short, and which peers might offer stronger long-term positioning. The comparison isn't always straightforward, but breaking it into clear dimensions helps investors make better-informed decisions. Key takeaways Comparing Amgen to competitors requires looking at revenue growth rates, operating margins, and pipeline depth rather than relying on any single metric. Amgen has historically posted strong profit margins relative to peers, but its revenue growth trajectory has lagged some faster-growing biotech names. Valuation multiples for large-cap biotech companies vary widely depending on pipeline optionality and patent cliff exposure. Competitive moats in biotech come from proprietary drug platforms, biosimilar portfolios, and the ability to replace revenue lost to patent expirations. No single company "wins" across every dimension, which is why a structured peer comparison matters. Who are Amgen's biggest competitors? Before you can compare Amgen to competitors, you need to define the peer group. Amgen operates in large-cap biotech and biopharma, which puts it in direct comparison with companies like Gilead Sciences, Regeneron Pharmaceuticals, AbbVie, and Vertex Pharmaceuticals. Each of these companies has a different mix of revenue sources, pipeline assets, and growth profiles. Some investors also include traditional pharma giants like Pfizer or Merck in an Amgen peer comparison, but the business models differ enough that the comparison gets muddy. The cleanest AMGN vs peers analysis focuses on companies with similar market caps, similar reliance on biologic drugs, and similar exposure to patent lifecycle dynamics. Peer group: A set of companies with comparable business models, market capitalizations, and industry exposure used as a benchmark for evaluating a specific stock. Choosing the right peer group matters because a poorly matched comparison can lead to misleading conclusions about valuation or performance. You can explore Amgen's financial profile on Rallies.ai to see how it stacks up on the metrics that matter most. How does Amgen's revenue growth compare to peers? Revenue growth is where the Amgen vs competitors debate gets interesting. Amgen is a mature biotech company, and mature companies tend to grow slower than mid-cap peers still ramping blockbuster drugs. Historically, Amgen's revenue growth has been in the low-to-mid single digits on an annualized basis, driven by a mix of legacy franchises and newer launches. Compare that to Regeneron, which has seen periods of double-digit revenue growth fueled by Dupixent and Eylea, or Vertex, which has maintained strong growth through its dominance in cystic fibrosis treatments. Gilead, on the other hand, has experienced stretches of flat or declining revenue as its hepatitis C franchise matured, only to see a boost from HIV therapies. Here's what to look for when you compare Amgen to competitors on growth: Organic growth rate: Strip out acquisitions and one-time items. What's the underlying growth engine? Product concentration: How much revenue depends on the top one or two drugs? High concentration means high risk when patents expire. Biosimilar contribution: Amgen has a growing biosimilar portfolio that adds incremental revenue. Not all peers have this advantage. New launch trajectory: Are recently approved drugs gaining market share quickly, or struggling against entrenched competition? The takeaway isn't that Amgen's growth is "bad." It's that growth rates need context. A company growing at 4% with 40% operating margins might create more shareholder value than one growing at 12% with 15% margins. Profit margins: Where Amgen stands out This is one area where Amgen has historically held an edge. The company has consistently posted operating margins in the range of 35% to 45%, which puts it near the top of its peer group. That kind of profitability reflects a combination of pricing power, manufacturing scale in biologics, and a mature cost structure. When you compare Amgen to competitors on margins, a few patterns emerge: Regeneron also runs high margins, partly because Dupixent economics are strong and the company has relatively lean operations. Gilead has solid margins but has faced pressure from generic competition in certain franchises. AbbVie carries higher debt loads from acquisitions (notably Allergan), which can weigh on net margins even when operating margins look healthy. Vertex has improved margins significantly as its cystic fibrosis portfolio scaled, but it reinvests heavily in R&D for pipeline diversification. Operating margin: The percentage of revenue left after subtracting operating expenses like cost of goods sold, R&D, and selling costs. Higher operating margins generally indicate stronger pricing power or better cost discipline, both of which matter in capital-intensive industries like biotech. Margins alone don't tell the full story. A company with sky-high margins but no growth is essentially a cash cow, and the question becomes how effectively that cash gets deployed into new drugs, share buybacks, or dividends. Valuation: Does AMGN deserve a premium or discount? Valuation is where the Amgen peer comparison gets most debatable. Biotech valuations are driven by a messy combination of current earnings, pipeline potential, and patent cliff risk. Two companies with identical revenue can trade at wildly different multiples depending on what the market thinks about their next five years. Common valuation metrics for an AMGN vs peers comparison include: Price-to-earnings (P/E): Large-cap biotech P/E ratios typically range from 10x to 25x, with higher multiples going to companies with stronger growth profiles or deeper pipelines. EV/EBITDA: Enterprise value to EBITDA normalizes for differences in capital structure and tax situations. Useful when one peer carries significantly more debt than another. PEG ratio: Price-to-earnings divided by expected earnings growth. Helps adjust for the fact that faster growers "deserve" higher P/E ratios. Price-to-free-cash-flow: Especially relevant for Amgen, which generates substantial free cash flow relative to its market cap. Amgen has historically traded at a modest discount to peers like Regeneron and Vertex, which makes sense given the growth differential. But that discount can narrow or widen depending on pipeline catalysts, acquisition activity, and broader market sentiment toward large-cap biotech. The question investors need to answer: Is the discount justified by slower growth, or does it represent an opportunity because the market is undervaluing Amgen's cash generation and pipeline optionality? That's a judgment call, and the right answer depends on your investment framework. You can dig deeper into valuation comparisons using the Rallies.ai Vibe Screener to filter biotech stocks by the metrics that matter most to you. Competitive moats: What protects each company? A competitive moat in biotech looks different from a moat in, say, consumer goods. There are no brand loyalty effects for a cancer drug. Instead, moats come from intellectual property, regulatory barriers, manufacturing complexity, and switching costs for physicians and payers. Here's how the moat picture breaks down in an Amgen vs competitors framework: Amgen: Deep expertise in biologic manufacturing, one of the largest biosimilar portfolios globally, and a broad base of established drugs across oncology, bone health, cardiovascular, and inflammation. The biosimilar business is a moat in itself because few companies can manufacture complex biologics at scale. Regeneron: Strong moat around its VelociSuite antibody discovery platform, which has produced multiple blockbusters. The technology platform itself is a competitive advantage that's hard to replicate. Vertex: Near-monopoly in cystic fibrosis, which provides a reliable cash flow base. The risk is concentration; the moat is narrow but deep. Gilead: Dominant position in HIV treatment with high switching costs (patients rarely change regimens that are working). Weaker position in other therapeutic areas. AbbVie: Diversified portfolio post-Allergan acquisition, strong position in immunology with Skyrizi and Rinvoq replacing Humira revenue. Economic moat: A durable competitive advantage that protects a company's market share and profitability over time. In biotech, moats often come from patent protection, manufacturing barriers, or proprietary drug discovery platforms rather than brand recognition. What are the biggest risks for each competitor? Risk is the other side of the coin when you compare Amgen to competitors, and every company in this peer group faces distinct threats. Amgen's risks: Patent expirations on legacy drugs, integration challenges from large acquisitions, and the question of whether newer launches can offset revenue declines from older products. The company also carries meaningful debt, which limits financial flexibility during downturns. Regeneron's risks: Heavy reliance on a small number of products. If Dupixent growth slows faster than expected, the market would likely re-rate the stock significantly. Vertex's risks: Pipeline diversification is the big question mark. Cystic fibrosis is a reliable franchise, but investors are paying for future expansion into pain, kidney disease, and gene editing. If those programs disappoint, the valuation could compress. Gilead's risks: An aging HIV franchise and limited success diversifying into oncology and inflammation beyond a few key products. AbbVie's risks: The Humira biosimilar cliff has arrived, and the company is betting heavily on Skyrizi and Rinvoq to fill the gap. Execution risk is real. The point of this comparison isn't to declare a winner. It's to recognize that each company has a different risk profile, and what matters is whether you're being compensated for those risks through valuation. How to build your own Amgen peer comparison Running your own analysis is more useful than relying on someone else's. Here's a practical approach: Define your peer group. Pick three to five companies in the same industry with similar market caps. Too many peers dilutes the comparison; too few gives a skewed picture. Choose your dimensions. Revenue growth, operating margins, free cash flow yield, P/E ratio, and pipeline depth are a solid starting set. Normalize the data. Use trailing twelve-month figures or multi-year averages rather than a single quarter, which can be noisy. Look for outliers. If one company's margin is 20 percentage points above the group, ask why. Is it sustainable, or is it a one-time benefit? Weigh the qualitative factors. Pipeline catalysts, management track record, and capital allocation history all matter but don't show up in a simple metrics table. The Rallies AI Research Assistant can help you pull together this kind of side-by-side analysis quickly, so you spend less time gathering data and more time interpreting it. Try it yourself Want to run this kind of analysis on your own? Copy any of these prompts and paste them into the Rallies AI Research Assistant: Compare Amgen to its biggest biotech competitors on revenue growth, profit margins, and pipeline strength — which companies have the most durable competitive advantages, and where does AMGN stand on valuation relative to peers? Compare Amgen to its closest competitors side by side — revenue growth, margins, valuation, and competitive position. What are the biggest risks facing Amgen, Regeneron, Vertex, and Gilead over the next few years, and how does each company's pipeline address those risks? Try Rallies.ai free → Frequently asked questions How do you compare Amgen to competitors effectively? The most useful approach is a structured peer comparison across multiple dimensions: revenue growth, profit margins, valuation multiples, pipeline depth, and risk factors. Looking at any single metric in isolation can be misleading, especially in biotech where pipeline optionality can justify significant valuation premiums. What does an AMGN vs peers analysis typically show? An AMGN vs peers analysis generally shows that Amgen leads on profitability and cash flow generation but trails some competitors on revenue growth. Its valuation often reflects this trade-off, with the stock trading at a discount to faster-growing peers like Regeneron or Vertex. Whether that discount represents value depends on how you weigh growth against stability. Which biotech companies are Amgen's closest competitors? Amgen's most commonly cited peers include Gilead Sciences, Regeneron Pharmaceuticals, AbbVie, and Vertex Pharmaceuticals. These companies operate at similar scale in biologics and biopharma, though each has a distinct therapeutic focus and growth profile. Is Amgen's biosimilar business a competitive advantage? It can be. Amgen has one of the largest biosimilar portfolios among major biotech companies, which provides incremental revenue and diversification. Manufacturing complex biologics at scale is difficult, and few competitors have matched Amgen's investment in this area. That said, biosimilar margins are typically lower than branded drug margins. What valuation metrics matter most in an Amgen peer comparison? P/E ratio, EV/EBITDA, PEG ratio, and price-to-free-cash-flow are all useful. P/E is the most widely cited, but PEG adjusts for growth differences between peers, which makes it more informative when comparing a slower grower like Amgen to a faster grower like Vertex. Free cash flow yield is especially relevant for investors focused on capital returns. How does pipeline strength factor into biotech valuations? Pipeline strength is one of the biggest drivers of valuation premiums in biotech. A company with multiple late-stage drug candidates in large markets will typically trade at a higher multiple than one with a thin pipeline, even if current earnings are similar. The challenge is that pipeline value is speculative and subject to binary clinical trial outcomes. What risks should investors consider when comparing Amgen to competitors? Patent expirations, product concentration, debt levels, pipeline execution, and competitive dynamics within specific therapeutic areas are all relevant risks. Each company in the peer group faces a different combination of these threats, and the goal of an Amgen peer comparison is to assess whether the stock's valuation adequately compensates for its specific risk profile. Can AI tools help with biotech competitor analysis? Yes. AI-powered research platforms can speed up the data-gathering and comparison process significantly. Tools like the Rallies AI Research Assistant let you ask natural-language questions about company financials, peer comparisons, and valuation metrics, which saves time compared to pulling data from multiple sources manually. Bottom line An Amgen vs competitors analysis comes down to trade-offs. Amgen offers strong margins, reliable cash flow, and a diversified portfolio, but it trails some peers on growth and faces real questions about patent cliffs and acquisition integration. No single biotech company wins across every dimension, which is exactly why doing this kind of structured comparison matters. The goal isn't to find the "best" stock; it's to understand what you're paying for and whether the risk-reward makes sense within your portfolio. For more frameworks on evaluating individual stocks and running peer comparisons, explore the stock analysis guides on Rallies.ai . And remember, do your own research before making any investment decisions. Disclaimer: This article is for educational and informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other type of advice. Rallies.ai does not recommend that any security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. All investments involve risk, including the possible loss of principal. Past performance does not guarantee future results. Before making any investment decision, consult with a qualified financial advisor and conduct your own research. Written by Gav Blaxberg , CEO of WOLF Financial and Co-Founder of Rallies.ai.
